Therefore, the risk of G6PD deficiency should be identified prior to receiving anti-relapse treatment of vivax malaria, and that the genotype and enzyme activity of CYP2D6 should be tested as well [14, 16, 17]. The gene discussed is CYP2D6; the disease is Plasmodium vivax malaria.